Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
EVMN · Why this verdict
Why Evommune (EVMN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Evommune models an extremely favorable risk/reward asymmetry of 7.27, with 109.1% modeled upside to the analyst-target take-profit against just 15.0% downside to stop. Reward-to-risk math | The asymmetry ratio should remain well above the 1.5 gate as long as the wide gap between analyst target and current price persists. | →Stable |
| CounterAs a binary-outcome clinical-stage biotech already down 61% from its 52-week high, the modeled upside depends heavily on clinical or regulatory catalysts that could just as easily go to zero as to the analyst target, making the ratio less reliable than in a typical operating business. | ||
Quality has breached the engine's minimum floor at 3.0 out of 10 against the 4.0 threshold, driven by extreme cash burn (free cash flow at -575% of revenue) and no competitive moat, triggering an exit recommendation. Warnings | Quality score should remain below the 4.0 floor as long as the company remains pre-commercial and burning cash at this rate. | →Stable |
| CounterPre-revenue clinical-stage biotechs are structurally cash-burning by design during trials, so a low quality score here reflects business-model stage rather than a controllable execution failure. | ||
Momentum has failed the engine's gate badly, scoring just 2.2 against the 4.5 minimum, driven by falling on-balance volume. Warnings | Momentum score should remain below 4.5 as long as volume distribution continues to fall. | →Stable |
| CounterMomentum in binary-outcome biotech names can reverse instantly and violently on a single clinical trial readout or regulatory update, making the current weak momentum reading a poor predictor of the next move. | ||
Insider selling has failed the engine's insider gate at the heavy severity level, with insiders selling $2.28 million, 0.49% of market cap, over the past 90 days across 9 transactions and zero buys. Warnings | Insider selling severity should de-escalate from heavy as selling activity slows. | →Stable |
| CounterPost-IPO biotech insiders frequently sell on pre-scheduled selling plans (Rule 10b5-1) tied to lock-up expirations rather than a fresh negative view of clinical prospects. | ||
The risk notes explicitly flag that the elevated 18% short interest is justified, alongside a high implied volatility of 145% and price trading above the $10 max-pain level. Risk breakdown | Short interest should remain elevated above 12% as long as the engine continues to view the bearish positioning as justified. | →Stable |
| CounterIn binary biotech setups, high short interest justified by weak fundamentals can reverse sharply into a short squeeze if a positive clinical catalyst hits, regardless of the underlying quality picture. | ||
Evommune models an extremely favorable risk/reward asymmetry of 7.27, with 109.1% modeled upside to the analyst-target take-profit against just 15.0% downside to stop.
→StableReward-to-risk math
- Expectation
- The asymmetry ratio should remain well above the 1.5 gate as long as the wide gap between analyst target and current price persists.
CounterAs a binary-outcome clinical-stage biotech already down 61% from its 52-week high, the modeled upside depends heavily on clinical or regulatory catalysts that could just as easily go to zero as to the analyst target, making the ratio less reliable than in a typical operating business.
Quality has breached the engine's minimum floor at 3.0 out of 10 against the 4.0 threshold, driven by extreme cash burn (free cash flow at -575% of revenue) and no competitive moat, triggering an exit recommendation.
→StableWarnings
- Expectation
- Quality score should remain below the 4.0 floor as long as the company remains pre-commercial and burning cash at this rate.
CounterPre-revenue clinical-stage biotechs are structurally cash-burning by design during trials, so a low quality score here reflects business-model stage rather than a controllable execution failure.
Momentum has failed the engine's gate badly, scoring just 2.2 against the 4.5 minimum, driven by falling on-balance volume.
→StableWarnings
- Expectation
- Momentum score should remain below 4.5 as long as volume distribution continues to fall.
CounterMomentum in binary-outcome biotech names can reverse instantly and violently on a single clinical trial readout or regulatory update, making the current weak momentum reading a poor predictor of the next move.
Insider selling has failed the engine's insider gate at the heavy severity level, with insiders selling $2.28 million, 0.49% of market cap, over the past 90 days across 9 transactions and zero buys.
→StableWarnings
- Expectation
- Insider selling severity should de-escalate from heavy as selling activity slows.
CounterPost-IPO biotech insiders frequently sell on pre-scheduled selling plans (Rule 10b5-1) tied to lock-up expirations rather than a fresh negative view of clinical prospects.
The risk notes explicitly flag that the elevated 18% short interest is justified, alongside a high implied volatility of 145% and price trading above the $10 max-pain level.
→StableRisk breakdown
- Expectation
- Short interest should remain elevated above 12% as long as the engine continues to view the bearish positioning as justified.
CounterIn binary biotech setups, high short interest justified by weak fundamentals can reverse sharply into a short squeeze if a positive clinical catalyst hits, regardless of the underlying quality picture.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Evommune shows an extremely favorable modeled risk/reward asymmetry typical of a binary biotech setup, but a quality-floor breach from heavy cash burn, a failed momentum gate, and heavy insider selling keep the engine on exit watch.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -575% of revenue
- ▸No competitive moat
Growth
5.0/10data confidence 50%Momentum
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 1.9 |
- ▸Volume distribution (falling OBV)
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 6.7 |
| Price target | 10.0 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 152%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $2,279,118 (0.488% of mkt cap)
Peer rank
3.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.1 |
| quality rank | 3.4 |
| growth rank | 5.0 |
Technical
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.4 |
| support resistance | 9.8 |
| 52w position | 0.0 |
Risk (lower is worse)
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.7 |
| days to cover | 0.4 |
| volatility | 0.0 |
| put call | 9.3 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| debt equity | 2.0 |
| news risk | 5.5 |
- ▸High short interest justified: 18%
- ▸High IV: 201%
- ▸Above max pain $10
Catalyst
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 2.5 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Estimates down -5.4% (30d)
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- ASYMMETRY:8.0>=1.5
- 8K:CLEAN
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.8<4.5
- INSIDER:0.49%=HEAVY
Warning (0)
none
Reward-to-Risk
7.95
Upside
+119.2%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -63% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.3 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:1.8<4.5.
The strongest dimensions are Sentiment at 7.3, Technical at 6.4, and Value at 5.4; the weakest are Momentum at 1.8, Risk (lower is worse) at 2.7, and Quality at 3.0. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 7.95 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Asymmetric Upside Biotech
Trip ifAsymmetry ratio falls below 1.5 from the current 7.27.
- P2Quality Floor Breach Cash Burn
Trip ifQuality score rises above 4.0 from the current 3.0, clearing the floor.
- P3Momentum Gate Failure
Trip ifMomentum score rises above 4.5 from the current 2.2, clearing the gate.
- P4Heavy Insider Selling
Trip ifInsider selling as a percentage of market cap falls below 0.15% over the next 90-day window, down from the current 0.49%.
- P5Elevated Short Interest Justified
Trip ifShort interest falls below 8% of float from the current 18%.